Basic Drug Info
Drug Name:Urobiotic
Other Info:Rx only70-1636-00-9December 1986

Clinical Trials:

Indications and Usage

Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows:"Lacking substantial evidence of effectiveness as a fixed combination":Urobiotic-250 is indicated in the therapy of a number of genitourinary infections caused by susceptible organisms.

These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis.

Since both Terramycin and sulfamethizole provide effective levels in blood, tissue, and urine, Urobiotic-250 provides a multiple antimicrobial approach at the site of infection.

Both antibacterial components are active against the most common urinary pathogens, including Escherichia coli, Pseudomonas aeruginosa, Aerobacter aerogenes, Streptococcus faecalis, Streptococcus hemolyticus, and Micrococcus pyogenes.

Urobiotic-250 is particularly useful in the treatment of infections caused by bacteria more sensitive to the combination than to either component alone.

The combination is also of value in those cases with mixed infections, and in those instances where the causative organism is unknown pending laboratory isolation.

Final classification of the less than effective indications requires further investigation.

Clinical studies to substantiate the efficacy of Urobiotic 250 are ongoing.

Completion of these ongoing studies will provide data for final classification of these indications.
Infection -- Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.

Pyelonephritis -- Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.

Pyelitis -- Inflammation of the KIDNEY PELVIS and KIDNEY CALICES where urine is collected before discharge, but does not involve the renal parenchyma (the NEPHRONS) where urine is processed.

Ureteritis --

Cystitis -- Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.

prostatitis -- Prostatitis: inflammation of the prostate, appreciated clinically as an enlarged, soft or tender prostate. Prostatic secretions contain large numbers of leukocytes.

Nonspecific urethritis --

Urethritis -- Inflammation involving the URETHRA. Similar to CYSTITIS, clinical symptoms range from vague discomfort to painful urination (DYSURIA), urethral discharge, or both.

Communicable Diseases -- broad class of diseases whose causative agents may be passed between individuals in many different ways.

This drug is contraindicated in individuals who have shown hypersensitivity to any of its components.This drug, because of the sulfonamide component, should not be used in patients with a history of sulfonamide sensitivities, and in pregnant females at term.
Hypersensitivity -- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.


If renal impairment exists, even usual oral or parenteral doses may lead to excessive systemic accumulation of the drug and possible liver toxicity.

Under such conditions, lower than usual doses are indicated and if therapy is prolonged, tetracycline serum level determinations may be advisable.

Oxytetracycline HCl, which is one of the ingredients of Urobiotic-250, may form a stable calcium complex in any bone-forming tissue with no serious harmful effects reported thus far in humans.

However, use of oxytetracycline during tooth development (last trimester of pregnancy, neonatal period and early childhood) may cause discoloration of the teeth (yellow-grey-brownish).

This effect occurs mostly during long term use of the drug but it also has been observed in usual short treatment courses.

Because of its sulfonamide content, this drug should be used only after critical appraisal in patients with liver damage, renal damage, urinary obstruction, or blood dyscrasias.

Deaths have been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia, and other blood dyscrasias associated with sulfonamide administration.

When used intermittently, or for a prolonged period, blood counts and liver and kidney function tests should be performed.

Certain hypersensitive individuals may develop a photodynamic reaction precipitated by exposure to direct sunlight during the use of this drug.

This reaction is usually of the photoallergic type which may also be produced by other tetracycline derivatives.

Individuals with a history of photosensitivity reactions should be instructed to avoid exposure to direct sunlight while under treatment with this or other tetracycline drugs, and treatment should be discontinued at first evidence of skin discomfort.NOTE: Reactions of a photoallergic nature are exceedingly rare with Terramycin (oxytetracycline HCl).

Phototoxic reactions are not believed to occur with Terramycin.

This web-site is for informational purposes only and is not intended as a substitute for advice from your doctor. It should not to be used for self-diagnosis or treatment.